Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized colistin in hospital-acquired pneumonia
NCT00920270Phase 3Unknown
- Sponsor
- Mahidol University
- Start
- Jun 2006
- Primary completion
- Mar 2010
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of colistin in hospital-acquired pneumonia (HAP), sponsored by Mahidol University. Primary endpoint: Clinical response at 14 days. Status: unknown.
02
Drugs
colistin
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on NCT00920270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00920270.